HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU
Clinical trials for HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU explained in plain language.
Never miss a new study
Get alerted when new HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU trials appear
Sign up with your email to follow new studies for HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New bladder cancer therapy shows promise in early trial
Disease control Recruiting nowThis phase 2 study is testing a new treatment called TARA-002 for people with a type of high-grade bladder cancer that hasn't spread into the muscle. The treatment is given directly into the bladder through a catheter once a week for 6 weeks. The study will include about 131 adul…
Matched conditions: HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU
Phase: PHASE2 • Sponsor: Protara Therapeutics • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New bladder cancer drug TARA-002 faces chemotherapy in major trial
Disease control Recruiting nowThis phase 3 trial tests whether a new drug, TARA-002, works better than standard chemotherapy for a type of early-stage bladder cancer. About 284 adults who have not received BCG therapy will be randomly assigned to receive either TARA-002 or chemotherapy directly into the bladd…
Matched conditions: HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU
Phase: PHASE3 • Sponsor: Protara Therapeutics • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC